The anti-tumor immune response involves a series of complex steps mediated by various immune cells and signaling molecules.

A new international study led by Prof. Carmit Levy of the Department of Human Genetics and Biochemistry at the Gray Faculty ...

Researchers headed by a team at the The Barcelona Institute of Science and Technology (BIST) Centre for Genomic Regulation (CRG) have discovered a protein, eukaryotic translation initiation factor 2A ...

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

Nine of the 10 most common cancer deaths in Australia are caused by solid tumours, but in most cases it’s the cancer’s spread to other parts of the body – known as metastasis – that proves fatal. Now, ...

This news could be tough to face. A new report from the Skin Cancer Foundation predicts that 234,680 cases of melanoma will ...

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...

There is strong evidence that the protein complex APC/C may function as a tumor suppressor in multiple cancers including lymphoma, colorectal and breast cancer, and now melanoma. A new study has ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...